ROSEN, A LONGSTANDING LAW FIRM, Encourages Milestone Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation - MIST

Milestone Pharmaceuticals -0.57%

Milestone Pharmaceuticals

MIST

1.75

-0.57%

NEW YORK , Dec. 30, 2023 /PRNewswire/ --

Rosen Law Firm, P.A. Logo

WHY: New York, N.Y., December 30, 2023. Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Milestone Pharmaceuticals Inc. (NASDAQ: MIST) resulting from allegations that Milestone may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Milestone securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=21411 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

WHAT IS THIS ABOUT: On December 26, 2023, before the market opened, Milestone Pharmaceuticals, Inc. announced that it had received a Refuse to File ("RTF") letter from the U.S. Food and Drug Administration ("FDA") for its recently submitted New Drug Application for its lead investigational product, etripamil, a self-administered nasal spray for the treatment of paroxysmal supraventricular tachycardia. In the RTF, the FDA noted that Milestone had not provided the agency with sufficient information to permit substantive review, and sought additional information related to the timing of adverse events in the drug's Phase 3 trial.

On this news, Milestone's stock fell $0.89 per share, or 30.90%, to close at $1.99 per share on December 26, 2023.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

    Laurence Rosen, Esq.

    Phillip Kim, Esq.

    The Rosen Law Firm, P.A.

    275 Madison Avenue, 40th Floor

    New York, NY 10016

    Tel: (212) 686-1060

    Toll Free: (866) 767-3653

    Fax: (212) 202-3827

    lrosen@rosenlegal.com

    pkim@rosenlegal.com

    cases@rosenlegal.com

    www.rosenlegal.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/rosen-a-longstanding-law-firm-encourages-milestone-pharmaceuticals-inc-investors-to-inquire-about-securities-class-action-investigation--mist-302024029.html

SOURCE THE ROSEN LAW FIRM, P. A.

Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via